16Jul 2023
Disconnect for Tezepelumab on Exacerbations, Symptoms, and Quality of Life in Type 2 Low Asthma

Disconnect for Tezepelumab on Exacerbations, Symptoms, and Quality of Life in Type 2 Low Asthma

A recent study of tezepelumab, a treatment for severe uncontrolled asthma, showed promising results in reducing exacerbations for patients with a specific type of asthma. However, the analysis also revealed a lack of efficacy in improving these patients' symptom control and quality of life. The study focused on individuals with low asthma characterized by low blood eosinophil counts and fractional exhaled nitric oxide levels. The differences between tezepelumab and placebo for secondary outcomes were not statistically significant or clinically relevant.

  • #critical care

Like

Save

Share